[Starforma] Basic Agreement on New Particle Beam Therapy｜July 2026

Overview of Business Strategy and Partnership

Starforma has signed a basic agreement with the National Institutes for Quantum Science and Technology (QST) Hospital to establish a collaborative research contract. This collaboration will explore a new cancer treatment method combining the company's BNCT drug 'Estborrowin®', which is manufactured and sold by the company, with particle research equipment owned by QST. Unlike conventional BNCT, this approach investigates a new mechanism of action utilizing particle beams, progressing from basic research through clinical trials with the aim of obtaining pharmaceutical approval. Details are expected to become clearer as research progresses and further contractual developments are made.

Future Outlook and Impact on Investors

The direct impact on performance for the fiscal year ending March 2027 is expected to be minimal; however, it could serve as a significant step towards the realization of new cancer treatment technologies in the long term. The company plans to continue discussions with QST and will provide timely updates on research progress and disclosures. This initiative is of interest to investors as a development in innovative medical technology.